A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells - PubMed (original) (raw)
. 2011 Feb 1;186(3):1538-45.
doi: 10.4049/jimmunol.1000951. Epub 2010 Dec 29.
Affiliations
- PMID: 21191066
- DOI: 10.4049/jimmunol.1000951
A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells
Tim D Holmes et al. J Immunol. 2011.
Abstract
NK cell activation is negatively regulated by the expression of target cell MHC class I molecules. We show that this relationship is nonlinear due to an NK cell activation/inhibition threshold. Ewing's sarcoma family tumor cell monolayers, which were highly susceptible to NK cells in vitro, developed a highly resistant phenotype when cultured as three-dimensional multicellular tumor spheroid structures. This suggested that tumor architecture is likely to influence the susceptibility to NK cells in vivo. Resistance of the multicellular tumor spheroid was associated with the increased expression of MHC class I molecules and greatly reduced NK cell activation, implying that a threshold of NK cell activation/inhibition had been crossed. Reducing MHC class I expression on Ewing's sarcoma family tumor monolayers did not alter their susceptibility to NK cells, whereas increased expression of MHC class I rendered them resistant and allowed the threshold point to be identified. This threshold, as defined by MHC class I expression, was predictive of the number of NK-resistant target cells within a population. A threshold permits modest changes in the target cell surface phenotype to profoundly alter the susceptibility to NK cells. Whereas this allows for the efficient detection of target cells, it also provides a route for pathogens and tumors to evade NK cell attack.
Similar articles
- NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC, Egeler RM, van Tol MJ, Schilham MW, Lankester AC. Verhoeven DH, et al. Mol Immunol. 2008 Sep;45(15):3917-25. doi: 10.1016/j.molimm.2008.06.016. Epub 2008 Jul 26. Mol Immunol. 2008. PMID: 18657862 - Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells.
Bridges KR, Smith BR. Bridges KR, et al. J Clin Invest. 1985 Sep;76(3):913-8. doi: 10.1172/JCI112089. J Clin Invest. 1985. PMID: 2995450 Free PMC article. - Requirements for control of B-cell lymphoma by NK cells.
Brenner CD, King S, Przewoznik M, Wolters I, Adam C, Bornkamm GW, Busch DH, Röcken M, Mocikat R. Brenner CD, et al. Eur J Immunol. 2010 Feb;40(2):494-504. doi: 10.1002/eji.200939937. Eur J Immunol. 2010. PMID: 19950185 - Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
Zhang C, Zhang J, Wei H, Tian Z. Zhang C, et al. Int Immunopharmacol. 2005 Jul;5(7-8):1099-111. doi: 10.1016/j.intimp.2005.03.003. Epub 2005 Apr 1. Int Immunopharmacol. 2005. PMID: 15914316 Review. - NK cells and cancer immunosurveillance.
Waldhauer I, Steinle A. Waldhauer I, et al. Oncogene. 2008 Oct 6;27(45):5932-43. doi: 10.1038/onc.2008.267. Oncogene. 2008. PMID: 18836474 Review.
Cited by
- Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.
Kearney CJ, Ramsbottom KM, Voskoboinik I, Darcy PK, Oliaro J. Kearney CJ, et al. Oncoimmunology. 2016 Jun 27;5(8):e1196308. doi: 10.1080/2162402X.2016.1196308. eCollection 2016 Aug. Oncoimmunology. 2016. PMID: 27622064 Free PMC article. - Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT.
Holmes TD, Wilson EB, Black EV, Benest AV, Vaz C, Tan B, Tanavde VM, Cook GP. Holmes TD, et al. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):E5688-96. doi: 10.1073/pnas.1411072112. Epub 2014 Dec 15. Proc Natl Acad Sci U S A. 2014. PMID: 25512551 Free PMC article. - Microphysiological systems as models for immunologically 'cold' tumors.
Gaebler D, Hachey SJ, Hughes CCW. Gaebler D, et al. Front Cell Dev Biol. 2024 Apr 22;12:1389012. doi: 10.3389/fcell.2024.1389012. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38711620 Free PMC article. Review. - Differential MHC class I expression in distinct leukocyte subsets.
Greene JM, Wiseman RW, Lank SM, Bimber BN, Karl JA, Burwitz BJ, Lhost JJ, Hawkins OE, Kunstman KJ, Broman KW, Wolinsky SM, Hildebrand WH, O'Connor DH. Greene JM, et al. BMC Immunol. 2011 Jul 15;12:39. doi: 10.1186/1471-2172-12-39. BMC Immunol. 2011. PMID: 21762519 Free PMC article. - APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells.
Peters HL, Yan Y, Solheim JC. Peters HL, et al. Oncoimmunology. 2013 Oct 1;2(10):e26293. doi: 10.4161/onci.26293. Epub 2013 Oct 8. Oncoimmunology. 2013. PMID: 24353913 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials